Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-02-28
2004-01-06
Aulakh, Charanjit S. (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06673944
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the preparation of warfarin sodium. Specifically, the invention relates to the direct preparation of pure warfarin sodium from warfarin acid at low temperature without decomposition using a polar organic solvent and an inorganic base.
2. Background
Warfarin sodium, known by the chemical name 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one sodium salt, is a well established, widely used oral anticoagulant and rodenticide. See, for example, U.S. Pat. No. 4,113,744 issued Sep. 12, 1978.) Warfarin sodium and its 2-ropanol clathrate are marketed under various commercial names like Coumadin; Marevan; Prothromadin; Tintorane; Warfarin sodium; Warfilone; Waran.
According to U.S. Pat. No. 3,192,232 to Schroeder and Link, warfarin sodium prepared by existing methods often has as undesirable slight yellow color. (See also, U.S. Pat. No. 3,077,481). Specifically, U.S. Pat. No. 3,192,232 describes aprocess for preparing warfarin sodium and warfarin potassium salts by reacting a slurry or warfarin acid in acetone-water with less than an equivalent of sodium hydroxide or potassium hydroxide in water at room temperature. The solution of the crude salt is purified by stirring with active charcoal and isolating of the salt by evaporation to dryness, spray drying, or drum drying.
U.S. Pat. No. 3,246,013 also emphasizes the difficulties encountered with the preparation of a high purity warfarin sodium. This patent discloses that the removal of the 2-propanol solvent from warfarin sodium 2-propanol clathrate cannot be achieved even with heating at 100° C. over P
2
O
5
for 3-5 hours in vacuum (0.1 mm Hg). U.S. Pat. No. 3,077,481 further discloses that heating the clathrate at higher temperatures (145° C.) in air at reduced pressure for prolonged time periods (24 hours) results in undesirable decomposition. Also, heating at still higher temperatures (230° C.), while successfully removing 2-propanol from the clathrate, results in rapid decomposition.
U.S. Pat. No. 2,765,321 to Schroeder et al. describes a process of preparing crystalline warfarin sodium by reacting an aqueous sodium hydroxide solution with an excess of warfarin acid, followed by removal of the excess acid by addition of ethanol and filtration. Pure warfarin sodium is obtained only after a salting out procedure using lithium chloride addition into the ethanol-water solution of the warfarin sodium salt, cooling and recovering the precipitated warfarin sodium by filtration.
U.S. Pat. No. 2,777,859 to Link et al. describes a process of preparing an aqueous solution of warfarin alkali metal derivatives by adding an aqueous alkali metal hydroxide to an excess of water wet warfarin acid, warming and removing the excess of warfarin acid by filtration.
Ohnishi et al. have described a method for preparing warfarin alkali metal salts by dissolving warfarin acid in an aqueous solution containing an equivalent amount of the respective alkali metal hydroxide (lithium, sodium, potassium, rubidium and cesium).
Biosci. Biotech. Biochem
. 1995, 59(6), 995-1006 (cf. CA 123: 105246 (1996 )) The respective salts are isolated by lyophilization.
In a recent patent, WO 97/24347 (published Jul. 10, 1997), Uwaydah et al. describe a comprehensive process for warfarin alkali salts (sodium and potassium) and clathrate preparation starting from 2-hydroxyacetophenone and a carbonate ester. The hydroxycoumarin thus obtained is further reacted with benzalacetone in the presence of a phase transfer catalyst to give warfarin acid. The latter intermediate is further reacted with sodium or potassium hydroxide or the carbonate, or preferably using sodium or potassium methoxide or ethoxide in anhydrous ethanol or 2-propanol to ultimately yield the desired product.
It is readily apparent that there is a great deal of interest in this field, and a number of synthetic routes for the preparation of warfarin sodium exist. However, existing procedures for the preparation of warfarin sodium have been hampered by several difficulties, notably:
The good solubility of warfarin sodium in most common polar solvents makes isolation difficult. This is further hampered by the immediate conversion of warfarin sodium to warfarin sodium 2-propanol clathrate when 2-propanol is used as a solvent;
Warfarin sodium tends to decompose in the presence of water and excess alkalinity, particularly as the temperature is increased; and
The production of dry free-flowing crystals is difficult.
Thus, the need remains for an economical, industrially feasible procedure to produce a high quality, pharmacopeial grade of warfarin sodium.
SUMMARY OF THE INVENTION
In summary, the invention is a method for producing warfarin sodium from warfarin acid in a direct, efficient, and industrially feasible manner. The method involves reacting warfarin acid with a volatalizable inorganic base, preferably sodium carbonate or sodium bicarbonate, in a stabilizing substantially anhydrous polar organic solvent such as ethanol at low temperature. Further purification and isolation is also conducted at moderate temperatures.
This invention solves a problem in the prior art where gel formation accompanies evaporation of the solvent during the preparation of warfarin sodium. In the present invention, gel formation is avoided.
The invention provides advantages not previously appreciated by providing a method for producing pure warfarin sodium wherein the reaction and filtration are conducted at ambient temperature. Furthermore, azeotropic distillation is eliminated entirely.
The invention offers an unforeseen advantage by conducting the final drying in conventional equipment using hot water or low pressure steam as a heating source. The invention is particularly advantageous in that warfarin sodium is not exposed to temperatures in excess of 100° C. which has been found to cause unfavorable decomposition.
This invention is in a crowded and mature art, but achieves the objective of a simple rapid production of warfarin sodium in an efficient, industrially feasible manner without cumbersome purification steps.
The invention differs from the prior art in modifications which were not previously known or suggested by using absolute ethanol as solvent and conducting the reaction and purification steps at low temperatures.
Further objectives and advantages will become apparent from a consideration of the description and examples.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In describing preferred embodiments of the present invention, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected. All references cited herein are incorporated by reference as if each had been individually incorporated by reference.
The present invention arises out of a need for a synthesis of warfarin sodium at low temperature. It was found that decomposition of the warfarin sodium occurs when produced by methods requiring elevated temperatures. Furthermore, in the presence of strong bases such as sodium hydroxide and sodium alkoxides normally used for the preparation of warfarin sodium, the warfarin sodium product decomposes, especially at elevated temperatures.
During development of the present invention, the following general parameters known in the art and described in the U.S. and British Pharmacopoeia were continually monitored, investigated and optimized:
(a) Stability of warfarin sodium and warfarin acid in different solvents and at different temperatures as measured by impurity test;
(b) Sensitivity of the reaction to pH control using various solvents, temperatures and bases as measured by pH test;
(c) Stability of warfarin sodium as a function of temperature and reaction time in the presence of excess base using the phenolic ketone test;
(d) Reaction times required when using solvents of differing polarities and using varying ratios of base;
(e) Crystallization of warfarin sodium from mixed solvents or by solvent evaporation; and
(f) Water content of the warfarin
Ashkar Michel
Bercovici Sorin
Graff Robert
Aulakh Charanjit S.
Gollin Michael A.
Haddaway Keith G.
Taro Pharmaceutical Industries Ltd.
Venable
LandOfFree
Preparation of warfarin sodium from warfarin acid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preparation of warfarin sodium from warfarin acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation of warfarin sodium from warfarin acid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3194047